5 completed, 3 not yet recruiting, 2 recruiting, 1 active not recruiting. 12 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 5, Not yet recruiting 3, Recruiting 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 2 | Recruiting 2 |
| Phase 3 | 1 | Completed 1 |
Follow Primary Aldosteronism: new trials by email Literature Review of Primary Aldosteronism trials Research Report on Primary Aldosteronism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism SAL0140 Tablets, SAL0140 placebo - Primary Aldosteronism | Phase 2 | Not yet recruiting | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 50 | 2026-06-12 | 2026-06-12 |
| Study of QLS1410 in the Treatment of Primary Aldosteronism. QLS1410, Placebo - Primary Aldosteronism | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2026-06-01 | 2026-04-24 |
| A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism HRS-1780 Tablets, Placebo - Primary Aldosteronism | Phase 2 | Active not recruiting | Shandong Suncadia Medicine Co., Ltd. | 61 | 2026-04-23 | 2026-10-13 |
| Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate [18F]CETO tracer, Dexamethasone oral, Adrenal vein sampling - Primary Aldosteronism | Phase 1 / Phase 2 | Recruiting | University Medical Center Groningen | 12 | 2024-11-06 | 2025-01-27 |
| Evaluation of [68Ga]Ga-PentixaFor PET Imaging for the Identification of Unilateral Adrenal Secretion of ALdosterON in Patients With Primary Aldosteronism [68Ga]Ga-PentixaFor PET imaging - Primary Aldosteronism | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 20 | 2024-06-01 | 2024-06-27 |
| Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism Al18F-NOTA-Pentixafor PET/CT - Primary Aldosteronism, Primary Aldosteronism Due to Aldosterone Producing Adenoma | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 150 | 2023-12-30 | 2025-02-26 |
| Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism [18-F]CETO - Primary Aldosteronism | Phase 2 | Unknown | University of Calgary | 30 | 2023-01-01 | 2024-07-24 |
| A Study of CIN-107 in Adults With Primary Aldosteronism CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing - Primary Aldosteronism, Hyperaldosteronism | Phase 2 | Completed | AstraZeneca | 15 | 2021-03-08 | 2026-03-03 |
| Calcium Channel Blockade in Primary Aldosteronism Amlodipine - Primary Aldosteronism, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral) | Phase 2 | Completed | Brigham and Women's Hospital | 15 | 2020-09-01 | 2025-04-15 |
| 11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre - Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism | Phase 2 / Phase 3 | Completed | Changi General Hospital | 97 | 2019-12-30 | 2026-10-26 |
| DP13 - A Phase II Study in Patients With Primary Aldosteronism dexfadrostat phosphate - Primary Aldosteronism | Phase 2 | Completed | Damian Pharma AG | 35 | 2019-11-21 | 2024-11-22 |
| Open-label Study on Treatment of Primary Aldosteronism With Everolimus Everolimus 0.75 mg - Primary Aldosteronism | Phase 2 | Completed | University Hospital, Basel, Switzerland | 12 | 2017-05-22 | 2019-01-09 |
Hyperaldosteronism (12) · Adrenal Gland Neoplasms (1) · Neoplasm Metastasis (1)
Adrenal Gland Diseases (12) · Adrenocortical Hyperfunction (12) · Endocrine System Diseases (12) · Endocrine Gland Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Amlodipine (1) · Dexamethasone (1) · Everolimus (1)
Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Brigham and Women's Hospital (1) · Changi General Hospital (1) · Damian Pharma AG (1) · Peking Union Medical College Hospital (1) · Qilu Pharmaceutical Co., Ltd. (1) · Shandong Suncadia Medicine Co., Ltd. (1) · Shenzhen Salubris Pharmaceuticals Co., Ltd. (1) · University Hospital, Basel, Switzerland (1) · University Medical Center Groningen (1) · University of Calgary (1)
China (3) · United States (2) · Canada (1) · France (1) · Italy (1) · Netherlands (1) · Singapore (1) · Switzerland (1)
Alexander Leung, MD (1) · Anand Vaidya, MD (1) · Dr. M.N. Kerstens (1) · Marc Y Donath, Prof. (1) · Paolo Mulatero, Prof (1)
PMID 33859526, PMID 36074157, PMID 37490693
2023 (2)